NEW YORK (GenomeWeb News) – The ALS Emergency Treatment Fund and Denovo Biomarkers today announced a partnership to evaluate Denovo's technology to identify patients who may best respond to amyotrophic lateral sclerosis drugs being studied.

The partnership will use Denovo's pharmacogenomic technology in order to identify biomarkers from biological samples from expanded access programs sponsored by ALS-ETF. Biomarkers which can be correlated with patient response to treatments may then be used to identify patient subsets for subsequent trials, the partners said.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The Jackson Laboratory has filed a complaint accusing Nanjing University of breeding and re-selling its mouse models, the Hartford Courant reports.

Oxford researchers are turning to virtual reality to visualize genes and regulatory elements, Phys.org says.

In Science this week: neutrophils rely on microRNA to protect against lung inflammation, and more.

China is moving forward with plans to sequence a million citizens, the Wall Street Journal reports.